Comparison of the TaqMan and LightCycler systems in pharmacogenetic testing: evaluation of CYP2C9*2/*3 polymorphisms

Clin Chem Lab Med. 2006;44(3):285-7. doi: 10.1515/CCLM.2006.049.

Abstract

Background: Pharmacogenetic testing for drug-metabolizing enzymes is not yet widely used in clinical practice.

Methods: In an attempt to facilitate the application of this procedure, we have compared two real-time PCR-based methods, the TaqMan and the LightCycler for the pharmacogenetic evaluation of CYP2C9*2/*3 polymorphisms.

Results and conclusion: Both procedures are suitable for pharmacogenetic studies. The TaqMan procedure was less expensive in terms of cost per sample, but the TaqMan apparatus is more expensive than the LightCycler apparatus.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Aryl Hydrocarbon Hydroxylases / genetics
  • Aryl Hydrocarbon Hydroxylases / metabolism*
  • Cytochrome P-450 CYP2C9
  • Humans
  • Pharmacogenetics / economics
  • Pharmacogenetics / methods*
  • Polymerase Chain Reaction / methods
  • Polymorphism, Genetic*
  • Sensitivity and Specificity
  • Taq Polymerase / genetics
  • Taq Polymerase / metabolism*
  • Temperature

Substances

  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Taq Polymerase